Lanvis

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Tioguanine 40mg

Available from:

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics

INN (International Name):

Tioguanine 40 mg

Dosage:

40 mg

Pharmaceutical form:

Tablet

Composition:

Active: Tioguanine 40mg Excipient: Acacia Lactose monohydrate Magnesium stearate Potato starch Stearic acid

Units in package:

Bottle, 25 tablets

Class:

Prescription

Prescription type:

Prescription

Manufactured by:

Ampac Fine Chemicals LLC

Therapeutic indications:

LANVIS is indicated primarily for the treatment of acute leukaemias especially:- · acute myelogenous leukaemia · acute lymphoblastic leukaemia

Product summary:

Package - Contents - Shelf Life: Bottle, - 25 tablets - 60 months from date of manufacture stored at or below 25°C

Authorization date:

1974-04-18

Patient Information leaflet

 
1 
LANVIS™ 
Thioguanine tablets 40mg 
___________________________________________________________________________________________________ 
Consumer Medicine Information 

WHAT IS IN THIS LEAFLET 

Please  read  this  leaflet  carefully 
before  you  start  taking  LANVIS 
tablets. 

This  leaflet  answers  some  common 
questions  about  LANVIS  tablets.  It 
does  not  contain  all  the  available 
information. 

It  does  not  take  the  place  of  talking 
to your doctor or pharmacist. 

All  medicines  have  risks  and 
benefits.  Your  doctor  has  weighed 
the  expected  benefits  of  you  taking 
LANVIS  against  the  risks  this 
medicine could have for you. 

If  you  have  any  concerns  about 
taking  this  medicine,  ask  your 
doctor or pharmacist. 

Keep 
this 
leaflet 
with 
your 
medicine.  You  may  need  to  read  it 
again. 

WHAT  LANVIS  IS  USED 
FOR 

LANVIS 
contains 
the 
active 
ingredient thioguanine. 

LANVIS  is  used  to  treat  acute 
myelogenous  leukaemia  and  acute 
lymphoblastic leukaemia. It can also 
be used to treat chronic granulocytic 
leukaemia. These are different types 
of  cancer  affecting  the  blood.  In 
people  with  blood  cancer,  abnormal 
blood cells are  
formed  in  the  bone  marrow  which 
multiply  uncontrollably,  crowding 
out  and  interfering  with  the  vital 
functions  of  normal  healthy  blood 
cells. 

Your  doctor  may  have  prescribed 
LANVIS for another purpose. 

LANVIS  belongs  to  a  group  of 
medicines 
called 
anti-neoplastic 
agents.  Within  this  group,  LANVIS 
belongs  to  a  class  of  medicines 
called  purine  antimetabolites.  These 
medicines  are  used  to  treat �

Summary of Product characteristics

LANVIS
TM
Thioguanine Tablets 40mg_Datasheet_New Zealand
1
DATA SHEET
1.
PRODUCT NAME (STRENGTH PHARMACEUTICAL FORM)
LANVIS
TM
(Tioguanine Tablets 40mg)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
White to off-white tablet, round, biconvex scored and debossed with
‘T40’ on one side
and plain on the other side.
3.
PHARMACEUTICAL FORM
Tablets
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
LANVIS is indicated primarily for the treatment of acute leukaemias
especially:-
Acute myelogenous leukaemia
Acute lymphoblastic leukaemia
LANVIS is also used in the treatment of chronic granulocytic
leukaemia.
4.2 DOSE AND METHOD OF ADMINISTRATION
The exact dose and duration of administration will depend on the
nature and dosage
of other cytotoxic drugs given in conjunction with LANVIS.
LANVIS is variably absorbed following oral administration and plasma
drug levels may
be reduced following emesis or intake of food.
Tioguanine can be used at any stage prior to maintenance therapy in
short term cycles
e.g. induction, consolidation, intensification. However, it is not
recommended for use
during maintenance therapy or similar long term continuous treatments
due to the high
risk of liver toxicity (see Special Warnings and Special Precautions
for Use and
Undesirable Effects).
ADULTS:-FOR ADULTS, THE USUAL DOSAGE OF LANVIS IS BETWEEN 60 AND
200MG/M2
BODY SURFACE AREA PER DAY.
CHILDREN:
For children, similar dosages to those used in adults, with
appropriate correction for
body surface area, have been used.
ELDERLY PATIENTS:
There are no specific dosage recommendations in elderly patients. (See
Dosage in
renal or hepatic impairment).
LANVIS has been used in various combination chemotherapy schedules in
elderly
patients with acute leukaemia at equivalent dosages to those used in
younger patients.
LANVIS
TM
Thioguanine Tablets 40mg_Datasheet_New Zealand
2
DOSAGE IN RENAL OR HEPATIC IMPAIRMENT:-
Consideration should be given to reducing the dosage in patients with
impaired hepatic
or renal function.
DOSING FOR TPMT-DEFICIENT PATIEN